Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KPTI Karyopharm Therapeutics	$3.54 -5.3%	$8.05	$3.51 ▼ $24.75	$29.80M	0.11	79,214 shs	149,206 shs
OTLK Outlook Therapeutics	$1.22	$1.65	$0.87 ▼ $12.85	$39.06M	0.54	739,179 shs	332,771 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
VRCA Verrica Pharmaceuticals	$0.42 -4.9%	$0.64	$0.39 ▼ $11.41	$38.60M	1.44	564,168 shs	363,226 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KPTI Karyopharm Therapeutics	-10.10%	-42.55%	-52.96%	-63.13%	-83.49%
OTLK Outlook Therapeutics	-7.58%	-18.39%	-18.67%	-35.45%	-89.78%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VRCA Verrica Pharmaceuticals	+2.12%	-15.30%	-31.87%	-36.83%	-92.53%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KPTI Karyopharm Therapeutics	3.6326 of 5 stars	3.5	0.0	0.0	4.6	2.4	1.7	0.6
OTLK Outlook Therapeutics	1.5644 of 5 stars	3.4	1.0	0.0	0.0	2.7	0.0	0.6
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	4.1527 of 5 stars	3.1	1.0	0.0	4.7	2.4	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KPTI Karyopharm Therapeutics	3.00	Buy	$57.50	1,524.29% Upside
OTLK Outlook Therapeutics	2.80	Moderate Buy	$10.20	736.07% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	2.20	Hold	$9.50	2,158.68% Upside

Current Analyst Ratings Breakdown

Latest PHXM, OTLK, KPTI, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/12/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00
2/26/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $56.00
2/24/2025	OTLK Outlook Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $24.00
2/20/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $45.00
2/20/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00
2/18/2025	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
2/18/2025	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $3.00
2/10/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $45.00
1/17/2025	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
1/17/2025	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KPTI Karyopharm Therapeutics	$145.24M	0.21	N/A	N/A	($1.47) per share	-2.41
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.57) per share	N/A
PHXM PHAXIAM Therapeutics	$32.66M	0.32	N/A	N/A	$7.98 per share	0.39
VRCA Verrica Pharmaceuticals	$7.57M	5.10	N/A	N/A	$0.47 per share	0.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KPTI Karyopharm Therapeutics	-$143.10M	-$15.29	N/A	N/A	N/A	-52.62%	N/A	-39.58%	5/6/2025 (Estimated)
OTLK Outlook Therapeutics	-$75.37M	-$7.42	N/A	N/A	N/A	N/A	N/A	-225.12%	5/21/2025 (Estimated)
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	-$67M	-$1.54	N/A	N/A	N/A	-625.06%	-591.84%	-141.63%	5/12/2025 (Estimated)

Latest PHXM, OTLK, KPTI, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/11/2025	Q4 2024	VRCA Verrica Pharmaceuticals	-$0.25	-$0.24	+$0.01	-$0.24	$1.30 million	$0.34 million
2/19/2025	Q4 2024	KPTI Karyopharm Therapeutics	-$3.90	-$3.60	+$0.30	-$0.24	$30.29 million	$30.54 million
2/14/2025	Q1 2025	OTLK Outlook Therapeutics	-$0.85	-$0.89	-$0.04	$0.72	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
OTLK Outlook Therapeutics	N/A	0.32	0.64
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
VRCA Verrica Pharmaceuticals	N/A	1.34	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KPTI Karyopharm Therapeutics	66.44%
OTLK Outlook Therapeutics	11.20%
PHXM PHAXIAM Therapeutics	0.40%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
KPTI Karyopharm Therapeutics	2.75%
OTLK Outlook Therapeutics	4.80%
PHXM PHAXIAM Therapeutics	1.94%
VRCA Verrica Pharmaceuticals	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KPTI Karyopharm Therapeutics	380	8.42 million	122.72 million	Optionable
OTLK Outlook Therapeutics	20	32.02 million	30.48 million	Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
VRCA Verrica Pharmaceuticals	40	91.78 million	26.18 million	Optionable

PHXM, OTLK, KPTI, and VRCA Headlines

Recent News About These Companies

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now

April 1 at 11:00 AM | zacks.com

Harmony, Lungpacer, Verrica and Arbutus make C-suite hires

April 1 at 1:15 AM | bizjournals.com

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31 at 8:00 AM | globenewswire.com

Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer

March 28, 2025 | msn.com

Verrica Pharmaceuticals appoints Rosenberg as CMO

March 26, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

March 26, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

March 26, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress

March 13, 2025 | msn.com

RBC Capital Remains a Hold on Verrica Pharmaceuticals (VRCA)

March 12, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript

March 12, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript

March 11, 2025 | seekingalpha.com

Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c)

March 11, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals files $150M mixed securities shelf

March 11, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates

March 11, 2025 | msn.com

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025 | globenewswire.com

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

March 3, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 16.89%

February 27, 2025 | aaii.com

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

February 27, 2025 | zacks.com

Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference

February 26, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

February 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM, OTLK, KPTI, and VRCA Company Descriptions

Karyopharm Therapeutics NASDAQ:KPTI

$3.54 -0.20 (-5.35%)

Closing price 04:00 PM Eastern

Extended Trading

$3.54 0.00 (-0.14%)

As of 04:05 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Outlook Therapeutics NASDAQ:OTLK

$1.22 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 -0.02 (-1.56%)

As of 05:12 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 03/31/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.42 -0.02 (-4.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 -0.02 (-5.85%)

As of 06:00 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time